AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0

GCI-MF 80mg/500mg Tablet

Prescription Icon
Prescription Required

Marketer

Algen Healthcare Limited

Salt Composition

Gliclazide (80mg) + Metformin (500mg)

Overview GCI-MF 80mg/500mg Tablet

Combiflex 80mg/500mg tablets are classified as antidiabetic medications, combining two active ingredients to manage type 2 diabetes in adults. This medication helps regulate blood glucose levels. Combiflex 80mg/500mg tablets should be ingested with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may adjust based on your blood sugar response. Continue taking this medication as prescribed, even if feeling well or achieving good glucose control. Discontinuing without medical consultation can lead to elevated blood sugar, potentially causing kidney damage, vision impairment, neuropathy, and limb loss. This medication is part of a comprehensive diabetes management plan, incorporating a healthy diet, regular exercise, and weight management as recommended by your doctor. Lifestyle significantly impacts diabetes control. Common side effects include hypoglycemia (low blood sugar), characterized by sweating, dizziness, headache, and trembling; constipation; and vomiting. Always carry a rapid-acting glucose source, such as sugary foods or juice, to counter hypoglycemia, and maintain regular mealtimes. Alcohol consumption should be avoided as it elevates the risk of hypoglycemia. Other potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe kidney or liver disease. Individuals with a history of heart disease should consult their physician before use. Pregnant or breastfeeding women should seek medical advice prior to use. Regular blood glucose monitoring is essential, and your physician may order blood tests to check blood cell counts and liver function.

Uses of GCI-MF 80mg/500mg Tablet

Diabetes mellitus type 2

Major Benefits of GCI-MF 80mg/500mg Tablet:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the 80mg/500mg GCI-MF tablet whole; avoid chewing, crushing, or breaking it. Administer this medication with food.

Common Side effects of GCI-MF 80mg/500mg Tablet:

  • Hypoglycemia (low blood glucose level)
  • Headache
  • Dizziness
  • Diarrhea
  • Upper respiratory tract infection
  • Nausea
  • Flatulence
  • Constipation

How to use GCI-MF 80mg/500mg Tablet:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the entire tablet without chewing, crushing, or fracturing it. The GCI-MF 80mg/500mg tablet should be administered with a meal.

How GCI-MF 80mg/500mg Tablet works:

Gliclazide and metformin, at dosages of 80mg and 500mg respectively, are combined in the GCI-MF tablet.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining GCI-MF 80mg/500mg Tablet with alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

The medication GCI-MF 80mg/500mg tablets poses a confirmed risk to fetal development and should not be taken during pregnancy. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Seek medical advice before use.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of GCI-MF 80mg/500mg tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use GCI-MF 80mg/500mg tablets cautiously, potentially requiring dosage modification. Physician consultation is recommended. The use of GCI-MF 80mg/500mg tablets is contraindicated in those with severe kidney disease. Routine monitoring of kidney function is advised during treatment.

LiverLiverCAUTION

Patients with liver impairment should use GCI-MF 80mg/500mg tablets cautiously, potentially requiring dosage modification. Medical advice is essential. A lower initial dose is typically prescribed for those with mild to moderate liver disease; the medication is contraindicated in cases of severe hepatic dysfunction.

What if you forget to take GCI-MF 80mg/500mg Tablet :

Should you forget to take your GCI-MF 80mg/500mg Tablet, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About GCI-MF 80mg/500mg Tablet

LabelValue
Addictive None.
Medication Classification Diabetes medication

FAQs on GCI-MF 80mg/500mg Tablet

Gliclazide/Metformin 80mg/500mg tablets combine two medications to manage type 2 diabetes mellitus (DM) in adults. This dual therapy enhances blood sugar control when coupled with a healthy diet and regular physical activity. Gliclazide's action involves stimulating insulin secretion from the pancreas, while metformin reduces hepatic glucose output and increases insulin responsiveness. This formulation is unsuitable for treating type 1 DM.
GCI-MF 80mg/500mg tablets may cause frequent side effects such as low blood sugar (hypoglycemia), taste changes, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but serious adverse reactions, including lactic acidosis, are also possible. Prolonged treatment may result in vitamin B12 deficiency.
Indeed, taking GCI-MF 80mg/500mg tablets may lead to low blood sugar (hypoglycemia). Common signs of low blood sugar include nausea, headache, irritability, hunger pangs, sweating, lightheadedness, a rapid pulse, and feelings of anxiety or trembling. This risk increases if meals are skipped or delayed, alcohol is consumed, excessive exercise is undertaken, or other diabetes medications are used concurrently. Therefore, consistent blood sugar monitoring is crucial. Carrying glucose tablets, honey, or fruit juice is recommended.
Lactic acidosis, a serious medical condition characterized by excessive blood lactic acid, is a potential consequence of taking GCI-MF 80mg/500mg tablets. This complication, also termed metformin-associated lactic acidosis (MALA), is infrequent but necessitates caution. Its occurrence is minimized by avoiding use in individuals with kidney impairment, the elderly, and those who consume significant alcohol. Warning signs of lactic acidosis might include muscular discomfort or weakness, vertigo, fatigue, cold extremities, respiratory distress, nausea, emesis, abdominal pain, and bradycardia. Should these symptoms appear, discontinue GCI-MF 80mg/500mg tablet use and seek immediate medical attention.
Prolonged GCI-MF 80mg/500mg Tablet use can indeed lead to vitamin B12 deficiency. This is because the medication hinders the stomach's absorption of vitamin B12. Untreated deficiency may result in anemia, neurological complications, including tingling and numbness in the extremities, muscle weakness, urinary dysfunction, cognitive impairment, and balance difficulties (ataxia). Preventive measures, suggested by some studies, include annual supplemental vitamin B12 intake.
Patients with hypersensitivity to any ingredient or inactive component within GCI-MF 80mg/500mg Tablet should not use this medication. Its use is also contraindicated in individuals with moderate to severe renal impairment or those experiencing metabolic acidosis, such as diabetic ketoacidosis.
Consuming alcohol while taking GCI-MF 80mg/500mg tablets is unsafe. This combination may worsen low blood sugar and raise the risk of lactic acidosis.
The GCI-MF 80mg/500mg tablet combines gliclazide and metformin to manage type 2 diabetes mellitus in adults. This medication enhances blood sugar control when used with a suitable diet and exercise regimen. Gliclazide stimulates insulin secretion from the pancreas, reducing blood glucose. Metformin reduces hepatic glucose production and improves insulin responsiveness. This dual-drug therapy is unsuitable for treating type 1 diabetes.
GCI-MF 80mg/500mg tablets may cause frequent side effects such as low blood sugar, taste disturbances, queasiness, abdominal discomfort, loose stools, headaches, and upper respiratory illnesses. Rare but potentially serious adverse reactions, including lactic acidosis, may also occur. Prolonged treatment can result in vitamin B12 depletion.
GCI-MF 80mg/500mg Tablets may induce hypoglycemia (low blood glucose). This can manifest as nausea, headache, irritability, hunger pangs, sweating, vertigo, tachycardia, and feelings of anxiety or tremor. The risk increases with skipped or delayed meals, alcohol consumption, strenuous activity, or concomitant use of other antidiabetic medications. Therefore, consistent blood glucose monitoring is crucial. Carrying glucose tablets, honey, or fruit juice is recommended.
GCI-MF 80mg/500mg Tablet use may result in lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed Metformin-associated lactic acidosis (MALA), this is an uncommon adverse reaction to metformin. Risk factors include pre-existing kidney impairment, advanced age, and significant alcohol consumption. Lactic acidosis symptoms can manifest as muscle aches or weakness, lightheadedness, fatigue, cold extremities, respiratory distress, nausea, vomiting, abdominal pain, or bradycardia. Should these symptoms appear, discontinue GCI-MF 80mg/500mg Tablet use and seek immediate medical attention.
Prolonged GCI-MF 80mg/500mg Tablet consumption can indeed lead to vitamin B12 deficiency. This is due to the medication's interference with the stomach's absorption of vitamin B12. Untreated, this deficiency can manifest as anemia, neurological complications such as tingling and numbness in the extremities, muscle weakness, urinary dysfunction, cognitive changes, and impaired balance. Preventive strategies proposed by some researchers include annual supplemental vitamin B12 intake.
Patients with a history of hypersensitivity to any GCI-MF 80mg/500mg Tablet constituent or inactive ingredient should not receive this medication. Its administration is also contraindicated in individuals with moderate to severe renal impairment or pre-existing metabolic acidosis, such as diabetic ketoacidosis.
Combining alcohol with GCI-MF 80mg/500mg tablets is unsafe. This combination may worsen low blood sugar and raise the risk of lactic acidosis.
GCI-MF 80mg/500mg Tablet
78
MRP 95
17% off